This study assessed whether premedication with dexamethasone reduces the incidence of IRs associated with HER2-targeted therapy.<h4>Methods</h4>In this randomized, multicenter trial, 100 patients with HER2-positive early breast cancer were randomized to receive dexamethasone either before (experimental group) or after (control group) HER2-targeted agents. Here, ERBB2 is linked to breast carcinoma.